GBGB1206628.8A
GB201206628D0
(en)
|
2012-04-16 |
2012-04-16 |
Subcutaneous administration of PEGylated blood clotting factors
|
GB1418864.3A
GB2516388A
(en)
|
2012-04-16 |
2013-04-16 |
Optimised subcutaneous therapeutic agents
|
CN201380027958.3A
CN104411335A
(en)
|
2012-04-16 |
2013-04-16 |
Optimised subcutaneous therapeutic agents
|
MYPI2014002900A
MY190257A
(en)
|
2012-04-16 |
2013-04-16 |
Optimised subcutaneous therapeutic agents
|
PE2014001639A
PE20150226A1
(en)
|
2012-04-16 |
2013-04-16 |
OPTIMIZED THERAPEUTIC AGENTS FOR SUBCUTANEOUS ADMINISTRATION
|
PCT/EP2013/057928
WO2013156488A2
(en)
|
2012-04-16 |
2013-04-16 |
Optimised subcutaneous therapeutic agents
|
MX2014012512A
MX2014012512A
(en)
|
2012-04-16 |
2013-04-16 |
Optimised subcutaneous therapeutic agents.
|
AP2014008049A
AP2014008049A0
(en)
|
2012-04-16 |
2013-04-16 |
Optimised subcuraneous therapeutic agents
|
GBGB1910190.6A
GB201910190D0
(en)
|
2012-04-16 |
2013-04-16 |
Optimised subsutaneous therapeutic agents
|
GBGB1910184.9A
GB201910184D0
(en)
|
2012-04-16 |
2013-04-16 |
Optimised subcutaneous therapeutic agents
|
BR112014025737A
BR112014025737A2
(en)
|
2012-04-16 |
2013-04-16 |
method for administering a therapeutic agent, method for preventing entry of a therapeutic agent, method for modulating the rate of release of a therapeutic agent, therapeutic agent, dosage forms, method of treating a disease and parts kit
|
KR1020147031042A
KR102137290B1
(en)
|
2012-04-16 |
2013-04-16 |
Optimised subcutaneous therapeutic agents
|
EA201491702A
EA033469B1
(en)
|
2012-04-16 |
2013-04-16 |
Subcutaneous administration of blood factor conjugates with polyethylene glycol
|
GEAP201313632A
GEP201706716B
(en)
|
2012-04-16 |
2013-04-16 |
Optimised subcutaneous therapeutic agents
|
IL235129A
IL235129B
(en)
|
2012-04-16 |
2013-04-16 |
Optimised subcutaneous therapeutic agents
|
JP2015504987A
JP2015512927A
(en)
|
2012-04-16 |
2013-04-16 |
Optimized subcutaneous therapy
|
AU2013248296A
AU2013248296A1
(en)
|
2012-04-16 |
2013-04-16 |
Optimised subcutaneous therapeutic agents
|
CA2869993A
CA2869993C
(en)
|
2012-04-16 |
2013-04-16 |
Optimised subcutaneous therapeutic agents
|
MD20140123A
MD20140123A2
(en)
|
2012-04-16 |
2013-04-16 |
Optimised subcutaneous therapeutic agents
|
US14/394,437
US20150086524A1
(en)
|
2012-04-16 |
2013-04-16 |
Optimised subcutaneous therapeutic agents
|
EP13719043.5A
EP2838566A2
(en)
|
2012-04-16 |
2013-04-16 |
Optimised subcutaneous therapeutic agents
|
IN8598DEN2014
IN2014DN08598A
(en)
|
2012-04-16 |
2013-04-16 |
|
SG11201406492YA
SG11201406492YA
(en)
|
2012-04-16 |
2013-04-16 |
Optimised subcutaneous therapeutic agents
|
NZ701205A
NZ701205A
(en)
|
2012-04-16 |
2013-04-16 |
Optimised subcutaneous therapeutic agents
|
ZA2014/07370A
ZA201407370B
(en)
|
2012-04-16 |
2014-10-10 |
Optimised subcutaneous therapeutic agents
|
CR20140475A
CR20140475A
(en)
|
2012-04-16 |
2014-10-14 |
OPTIMIZED SUBCUTANEOUS ADMINISTRATION THERAPEUTIC AGENTS
|
NI201400122A
NI201400122A
(en)
|
2012-04-16 |
2014-10-15 |
THERAPEUTIC AGENTS FOR OPTIMIZED SUBCUTANEOUS ADMINISTRATION
|
CL2014002773A
CL2014002773A1
(en)
|
2012-04-16 |
2014-10-15 |
A subcutaneous dosage form of a pharmaceutical composition of a blood coagulation factor selected from factor vii, viia, viii, ix, x, xa, xi, xiii, v, von willebrand factor and protein c, conjugated with a polyethylene glycol molecule (peg), where the dosage of the factor is 100 and 250 iu / kg or 25 and 50 iu / kg, and where the peg molecule is conjugated directly or indirectly.
|
PH12014502314A
PH12014502314A1
(en)
|
2012-04-16 |
2014-10-15 |
Optimised subcutaneous therapeutic agents
|
ECIEPI201423048A
ECSP14023048A
(en)
|
2012-04-16 |
2014-10-16 |
OPTIMIZED THERAPEUTIC AGENTS FOR SUBCUTANEOUS ADMINISTRATION
|
MX2020014208A
MX2020014208A
(en)
|
2012-04-16 |
2014-10-16 |
Optimised subcutaneous therapeutic agents.
|
CO14252826A
CO7151496A2
(en)
|
2012-04-16 |
2014-11-14 |
Therapeutic agents for optimized subcutaneous administration
|
HK15100881.5A
HK1200695A1
(en)
|
2012-04-16 |
2015-01-27 |
Optimised subcutaneous therapeutic agents
|
US15/691,090
US11351112B2
(en)
|
2012-04-16 |
2017-08-30 |
Optimised subcutaneous therapeutic agents
|
JP2017171545A
JP6550107B2
(en)
|
2012-04-16 |
2017-09-06 |
Optimized subcutaneous drug
|
AU2018200111A
AU2018200111B2
(en)
|
2012-04-16 |
2018-01-05 |
Optimised subcutaneous therapeutic agents
|
JP2019073048A
JP2019131593A
(en)
|
2012-04-16 |
2019-04-05 |
Optimized subcutaneous therapeutic agents
|
AU2020200842A
AU2020200842A1
(en)
|
2012-04-16 |
2020-02-06 |
Optimised subcutaneous therapeutic agents
|